Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Stock Forecast

Stock Price Forecast

The 22 analysts with 12-month price forecasts for Alnylam Pharmaceuticals stock have an average target of 305.86, with a low estimate of 220 and a high estimate of 400. The average target predicts an increase of 22.06% from the current stock price of 250.59.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$220	$305.86	$300	$400
Change	-12.21%	+22.06%	+19.72%	+59.62%

Analyst Ratings

The average analyst rating for Alnylam Pharmaceuticals stock from 23 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Sep '24	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25
Strong Buy	10	10	10	10	10	10
Buy	6	7	7	7	8	8
Hold	7	6	5	5	5	4
Sell	0	0	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	23	23	23	23	24	23

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $384 → $385	Strong Buy	Maintains	$384 → $385	+53.64%	Feb 18, 2025
Greg Harrison Scotiabank	Scotiabank	Buy Maintains $310 → $300	Buy	Maintains	$310 → $300	+19.72%	Feb 14, 2025
Michael Ulz Morgan Stanley	Morgan Stanley	Hold Maintains $275 → $284	Hold	Maintains	$275 → $284	+13.33%	Feb 14, 2025
Joseph Stringer Needham	Needham	Strong Buy Reiterates $320	Strong Buy	Reiterates	$320	+27.70%	Feb 14, 2025
Luca Issi RBC Capital	RBC Capital	Buy Reiterates $300	Buy	Reiterates	$300	+19.72%	Feb 11, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.75B

Increased by 22.50%

from 2.25B

Revenue Next Year

3.60B

Increased by 30.54%

from 2.75B

EPS This Year

-1.03

from -2.18

EPS Next Year

2.39

from -1.03

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	492.85M	844.29M	1.04B	1.83B	2.25B	2.75B	3.60B	4.43B
Revenue Growth	124.28%	71.31%	22.88%	76.23%	22.97%	22.50%	30.54%	23.23%
EPS	-7.46	-7.20	-9.30	-3.52	-2.18	-1.03	2.39	5.20
EPS Growth	-	-	-	-	-	-	-	117.80%
Forward PE	-	-	-	-	-	-	105.04	48.23
No. Analysts	-	-	-	-	-	34	27	16

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	3.6B	4.8B	6.8B
Avg	2.8B	3.6B	4.4B
Low	2.2B	2.8B	3.5B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	62.2%	73.9%	90.1%
Avg	22.5%	30.5%	23.2%
Low	-0.4%	2.3%	-2.3%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	2.83	6.47	8.98
Avg	-1.03	2.39	5.20
Low	-3.63	-1.75	2.01

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	276.3%
Avg	-	-	117.8%
Low	-	-	-15.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.